{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T22:13:40Z","timestamp":1768256020492,"version":"3.49.0"},"reference-count":39,"publisher":"Becaris Publishing Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p>\n            <jats:bold>Background:<\/jats:bold>\n            Real-world data on patients newly initiating ixekizumab is limited. Our study describes the characteristics of patients who initiated ixekizumab and other biologics for psoriasis treatment in North American dermatological practices.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            Characteristics of patients ascertained at registry enrollment are described via means and frequencies.\n            <jats:bold>Results:<\/jats:bold>\n            Compared with other biologic initiators, ixekizumab initiators had: longer disease duration (17.1 vs 15.1 years); more were considered least severe by body surface area (33\u00a0vs 26%); moderate-to-severe by IGA (56\u00a0vs 48%); were biologic-experienced (80\u00a0vs 52%); obese (54 vs 47%); and experienced greater impact in work productivity (5.3 vs 2.9%) versus other biologic initiators.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Psoriasis patients initiating ixekizumab had more severe disease, biologic experience, and worse patient-reported outcomes than those initiating other biologics.\n          <\/jats:p>","DOI":"10.2217\/cer-2020-0113","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T13:34:30Z","timestamp":1608730470000},"page":"157-167","source":"Crossref","is-referenced-by-count":4,"title":["Understanding characteristics of patients newly initiating ixekizumab: findings from the Corrona Psoriasis Registry"],"prefix":"10.57264","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1722-1892","authenticated-orcid":false,"given":"Jashin J","family":"Wu","sequence":"first","affiliation":[{"name":"Dermatology Research &amp; Education Foundation, Irvine, CA\u00a092620, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan W","family":"Harrison","sequence":"additional","affiliation":[{"name":"Corrona, LLC, Waltham, MA\u00a002451, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baojin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Eli Lilly &amp; Company, Indianapolis, IN\u00a046225, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orin M","family":"Goldblum","sequence":"additional","affiliation":[{"name":"Eli Lilly &amp; Company, Indianapolis, IN\u00a046225, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William N","family":"Malatestinic","sequence":"additional","affiliation":[{"name":"Eli Lilly &amp; Company, Indianapolis, IN\u00a046225, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7907-6400","authenticated-orcid":false,"given":"Russel","family":"Burge","sequence":"additional","affiliation":[{"name":"Eli Lilly &amp; Company, Indianapolis, IN\u00a046225, USA"},{"name":"Division of Pharmaceutical Sciences, Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH\u00a045229, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mwangi J","family":"Murage","sequence":"additional","affiliation":[{"name":"Eli Lilly &amp; Company, Indianapolis, IN\u00a046225, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"3","key":"e_1_3_6_3_2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States","volume":"70","author":"Rachakonda TD","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J. Am. Acad. Dermatol. 70(3), 512\u2013516 (2014).","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_3_6_4_2","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb JE","year":"2016","unstructured":"Greb JE, Goldminz AM, Elder JT Psoriasis. Nat. Rev. Dis. Primers 2, 16082 (2016).","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"21","key":"e_1_3_6_5_2","first-page":"S403","article-title":"Contemporary management of moderate to severe plaque psoriasis","volume":"23","author":"Wu JJ","year":"2017","unstructured":"Wu JJ. Contemporary management of moderate to severe plaque psoriasis. Am. J. Manag. Care 23(Suppl. 21), S403\u2013S416 (2017).","journal-title":"Am. J. Manag. Care"},{"issue":"12","key":"e_1_3_6_6_2","doi-asserted-by":"crossref","first-page":"e52935","DOI":"10.1371\/journal.pone.0052935","article-title":"Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation Survey data 2003-2011","volume":"7","author":"Armstrong AW","year":"2012","unstructured":"Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation Survey data 2003-2011. PLoS ONE 7(12), e52935 (2012).","journal-title":"PLoS ONE"},{"key":"e_1_3_6_7_2","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jaad.2007.07.023","article-title":"Association of patient-reported psoriasis severity with income and employment","volume":"59","author":"Horn EJ","year":"2007","unstructured":"Horn EJ, Fox KM, Patel V Association of patient-reported psoriasis severity with income and employment. J. Am. Acad. Dermatol. 59, 963\u2013971 (2007).","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_3_6_8_2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/09546630500482886","article-title":"The negative impact of psoriasis on the workplace","volume":"17","author":"Pearce DJ","year":"2006","unstructured":"Pearce DJ, Singh S, Balkrishnan R The negative impact of psoriasis on the workplace. J. Dermatolog. Treat. 17, 24\u201328 (2006).","journal-title":"J. Dermatolog. Treat."},{"issue":"4","key":"e_1_3_6_9_2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase III trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon KB","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA Phase III trials of ixekizumab in moderate-to-severe plaque psoriasis. N. Engl. J. Med. 375(4), 345\u2013356 (2016).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_6_10_2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjd.16050","article-title":"Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)","volume":"178","author":"Papp KA","year":"2018","unstructured":"Papp KA, Leonardi L, Blauvelt A Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br. J. Dermatol. 178, 674\u2013681 (2018).","journal-title":"Br. J. Dermatol."},{"key":"e_1_3_6_11_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s13555-016-0102-0","article-title":"Ixekizumab for the treatment of psoriasis: a review of Phase III trials","volume":"6","author":"Farahnik B","year":"2016","unstructured":"Farahnik B, Beroukhim K, Zhu TH Ixekizumab for the treatment of psoriasis: a review of Phase III trials. Dermatol. Ther. 6, 25\u201337 (2016).","journal-title":"Dermatol. Ther."},{"key":"e_1_3_6_12_2","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/jdv.14252","article-title":"The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three, randomized, controlled Phase III studies of patients with moderate-to-severe plaque psoriasis","volume":"31","author":"Reich K","year":"2017","unstructured":"Reich K, Puig L, Mallbris L The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three, randomized, controlled Phase III studies of patients with moderate-to-severe plaque psoriasis. J. Eur. Acad. Dermatol. Venereol. 31, 1196\u20131207 (2017).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"2","key":"e_1_3_6_13_2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jaad.2018.03.047","article-title":"Efficacy and safety of ixekizumab over 4 years of open-label treatment in a Phase II study in chronic plaque psoriasis","volume":"79","author":"Zachariae C","year":"2018","unstructured":"Zachariae C, Gordon K, Kimball A Efficacy and safety of ixekizumab over 4 years of open-label treatment in a Phase II study in chronic plaque psoriasis. J. Am. Acad. Dematol. 79(2), 294\u2013301 (2018).","journal-title":"J. Am. Acad. Dematol."},{"issue":"5","key":"e_1_3_6_14_2","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jaad.2017.06.153","article-title":"Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled Phase III trial (UNCOVER-3)","volume":"77","author":"Blauvelt A","year":"2017","unstructured":"Blauvelt A, Gooderham M, Iversen L Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled Phase III trial (UNCOVER-3). J. Am. Acad. Dermatol. 77(5), 855\u2013862 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_3_6_15_2","first-page":"1","article-title":"Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3","volume":"4","author":"Kemeny L","year":"2018","unstructured":"Kemeny L, Berggren L, Dossenbach M Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3. J. Dermatolog. Treat. 4, 1\u201327 (2018).","journal-title":"J. Dermatolog. Treat."},{"issue":"3","key":"e_1_3_6_16_2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2016.09.026","article-title":"Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparison and integrated data","volume":"76","author":"Strober B","year":"2017","unstructured":"Strober B, Leonardi C, Papp KA Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparison and integrated data. J. Am. Acad. Dermatol. 76(3), 432\u2013440 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_3_6_17_2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2147\/TCRM.S111107","article-title":"Role of IL-17 on plaque psoriasis: therapeutic potential of ixekizumab","volume":"13","author":"Hanley TL","year":"2017","unstructured":"Hanley TL, Yiu ZZN. Role of IL-17 on plaque psoriasis: therapeutic potential of ixekizumab. Ther. Clin. Risk Manag. 13, 315\u2013323 (2017).","journal-title":"Ther. Clin. Risk Manag."},{"issue":"2","key":"e_1_3_6_18_2","first-page":"232","article-title":"Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry","volume":"78","author":"Strober B","year":"2017","unstructured":"Strober B, Karki C, Mason M Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J. Am. Acad. Dermatol. 78(2), 232\u2013332 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_3_6_19_2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2004.04.012","article-title":"Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment","volume":"51","author":"Langley RG","year":"2004","unstructured":"Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J. Am. Acad. Dermatol. 51, 563\u2013569 (2004).","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/jid.2009.391","article-title":"How good are clinical severity and outcome measures for psoriasis? Quantitative evaluation in a systematic review","volume":"130","author":"Spuls PI","year":"2010","unstructured":"Spuls PI, Lecluse LL, Poulsen ML How good are clinical severity and outcome measures for psoriasis? Quantitative evaluation in a systematic review. J. Invest. Dermatol. 130, 933\u2013943 (2010).","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"e_1_3_6_21_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/09546634.2013.865009","article-title":"The 5-point Investigator's Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials","volume":"26","author":"Langley RG","year":"2015","unstructured":"Langley RG, Feldman SR, Nyirady J The 5-point Investigator's Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J. Dermatolog. Treat. 26(1), 23\u201331 (2015).","journal-title":"J. Dermatolog. Treat."},{"key":"e_1_3_6_22_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly MC","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4, 353\u2013365 (1993).","journal-title":"Pharmacoeconomics"},{"key":"e_1_3_6_23_2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use","volume":"19","author":"Finlay AY","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19, 210\u2013216 (1994).","journal-title":"Clin. Exp. Dermatol."},{"issue":"3","key":"e_1_3_6_24_2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol-a new facility for the measurement of health-related quality of life","volume":"16","author":"The EuroQol Group","year":"1990","unstructured":"The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16(3), 199\u2013208 (1990).","journal-title":"Health Policy"},{"issue":"1","key":"e_1_3_6_25_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s40629-016-0006-7","article-title":"Visual analogue scales (VAS): measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care","volume":"26","author":"Klimek L","year":"2017","unstructured":"Klimek L, Bergmann KC, Biedermann T Visual analogue scales (VAS): measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care. Allergo J. Int. 26(1), 16\u201324 (2017).","journal-title":"Allergo J. Int."},{"key":"e_1_3_6_26_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40257-017-0254-4","article-title":"Ixekizumab: a review in moderate-to-severe plaque psoriasis","volume":"18","author":"Syed YY","year":"2017","unstructured":"Syed YY. Ixekizumab: a review in moderate-to-severe plaque psoriasis. Am. J. Clin. Dermatol. 18, 147\u2013158 (2017).","journal-title":"Am. J. Clin. Dermatol."},{"key":"e_1_3_6_27_2","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/jdv.14237","article-title":"Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three Phase III trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)","volume":"31","author":"Menter A","year":"2017","unstructured":"Menter A, Warren RB, Langley RG Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three Phase III trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J. Eur. Acad. Dermatol. Venereol. 31, 1686\u20131692 (2017).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"e_1_3_6_28_2","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/bjd.15666","article-title":"Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a Phase II study","volume":"177","author":"Reich K","year":"2017","unstructured":"Reich K, Pinter A, Lacour JP Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a Phase II study. Br. J. Dermatol. 177, 1014\u20131023 (2017).","journal-title":"Br. J. Dermatol."},{"key":"e_1_3_6_29_2","first-page":"348","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial","volume":"182","author":"Blauvett A","year":"2020","unstructured":"Blauvett A, Papp K, Gotlieb AB A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br. J. Dermatol. 182, 348\u20131358 (2020).","journal-title":"Br. J. Dermatol."},{"key":"e_1_3_6_30_2","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/jdv.14211","article-title":"Rapid improvement in health-related quality of life and itch with ixekizumab treatment in randomized Phase III trials: Results from UNCOVER-2 and UNCOVER-3","volume":"31","author":"Leonardi CL","year":"2017","unstructured":"Leonardi CL, Blauvett A, Sofen HL Rapid improvement in health-related quality of life and itch with ixekizumab treatment in randomized Phase III trials: Results from UNCOVER-2 and UNCOVER-3. J. Eur. Acad. Dermatol. Venereol. 31, 1483\u20131490 (2017).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"6","key":"e_1_3_6_31_2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamadermatol.2016.0269","article-title":"Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized Phase III clinical trials","volume":"152","author":"Armstrong AW","year":"2016","unstructured":"Armstrong AW, Lynde CW, McBride SR Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized Phase III clinical trials. JAMA Dermatol. 152(6), 661\u2013669 (2016).","journal-title":"JAMA Dermatol."},{"issue":"3","key":"e_1_3_6_32_2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/jdv.14033","article-title":"Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phase of UNCOVER-3","volume":"31","author":"van de Kerkhof P","year":"2017","unstructured":"van de Kerkhof P, Guenther L, Gottlieb AB Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phase of UNCOVER-3. J. Eur. Acad. Dermatol. Venereol. 31(3), 447\u2013482 (2017).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"4","key":"e_1_3_6_33_2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1080\/09546634.2016.1249820","article-title":"Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three Phase III trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)","volume":"28","author":"Reich K","year":"2017","unstructured":"Reich K, Leonardi C, Lebwohl M Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three Phase III trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J. Dermatolog. Treat. 28(4), 282\u2013287 (2017).","journal-title":"J. Dermatolog. Treat."},{"key":"e_1_3_6_34_2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/jdv.13990","article-title":"Treatment outcomes with ixekizumab in patient with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies","volume":"31","author":"Gottlieb AB","year":"2017","unstructured":"Gottlieb AB, Lacour JP, Korman N Treatment outcomes with ixekizumab in patient with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies. J. Eur. Acad. Dermatol. Venereol. 31, 679\u2013685 (2017).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"8","key":"e_1_3_6_35_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.20619","article-title":"Step therapy-clinical algorithms, legislation, and optimal prescribing","volume":"317","author":"Fischer MA","year":"2017","unstructured":"Fischer MA, Avborn J. Step therapy-clinical algorithms, legislation, and optimal prescribing. JAMA 317(8), 801\u2013802 (2017).","journal-title":"JAMA"},{"key":"e_1_3_6_36_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s41669-019-0152-1","article-title":"Impact of plan-level access restrictions on effectiveness of biologics among patients with rheumatoid or psoriatic arthritis","volume":"4","author":"Boystov N","year":"2020","unstructured":"Boystov N, Zhang X, Evans KA Impact of plan-level access restrictions on effectiveness of biologics among patients with rheumatoid or psoriatic arthritis. Pharmacoecon. Open 4, 105\u2013117 (2020).","journal-title":"Pharmacoecon. Open"},{"key":"e_1_3_6_37_2","unstructured":"Banken R. Institute for Clinical and Economic Review. Draft evidence report: targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis-condition update (2018). https:\/\/icer-review.org\/wp-content\/uploads\/2017\/11\/ICER_Psoriasis_Update_Draft_Report_04272018.pdf"},{"key":"e_1_3_6_38_2","first-page":"1","article-title":"Institute for Clinical and Economic Review (ICER) Psoriasis Update 2018: what it means for dermatologists treating moderate-to-severe plaque psoriasis","volume":"22","author":"Lee EB","year":"2019","unstructured":"Lee EB, Pithadia DJ, Reynolds KA, Wu JJ. Institute for Clinical and Economic Review (ICER) Psoriasis Update 2018: what it means for dermatologists treating moderate-to-severe plaque psoriasis. J. Dermatolog. Treat. 22, 1\u20139 (2019).","journal-title":"J. Dermatolog. Treat."},{"issue":"6","key":"e_1_3_6_39_2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.diabet.2017.06.003","article-title":"Clinical inertia and its impact on treatment intensification in people with Type 2 diabetes mellitus","volume":"43","author":"Reach G","year":"2017","unstructured":"Reach G Clinical inertia and its impact on treatment intensification in people with Type 2 diabetes mellitus. Diabetes Metab. 43(6), 501\u2013511 (2017).","journal-title":"Diabetes Metab."},{"issue":"3","key":"e_1_3_6_40_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s11606-007-0470-3","article-title":"Patients\u2019 beliefs and preferences regarding doctors\u2019 medication reccomendations","volume":"23","author":"Goff SL","year":"2008","unstructured":"Goff SL, Mazor KM, Meterko V Patients\u2019 beliefs and preferences regarding doctors\u2019 medication reccomendations. J. Gen. Intern. Med. 23(3), 236\u2013241 (2008).","journal-title":"J. Gen. Intern. Med."},{"key":"e_1_3_6_41_2","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","article-title":"Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey","volume":"70","author":"Lebwohl MG","year":"2014","unstructured":"Lebwohl MG, Bachelez H, Barker J Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J. Am. Acad. Dermatol. 70, 871\u2013881 (2014).","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2020-0113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:42:53Z","timestamp":1679229773000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2020-0113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.2217\/cer-2020-0113"],"URL":"https:\/\/doi.org\/10.2217\/cer-2020-0113","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}